Guided P2Y12 inhibitor selection after rapid CYP2C19 genotyping in patients undergoing percutaneous coronary intervention
EuroIntervention · 2026
DOI: 10.4244/eij-d-26-00473 ↗Kurz gefasst
Fachartikel in der Zeitschrift EuroIntervention, 2026. Verfasst von Cameron D Thomas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Flo…. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Percutaneous Coronary Intervention, Purinergic P2Y Receptor Antagonists, Platelet Aggregation Inhibitors. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHGRI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Dual antiplatelet therapy remains the standard treatment following percutaneous coronary intervention (PCI). While prasugrel and ticagrelor offer consistent antiplatelet effects, they increase bleeding risk compared with clopidogrel, which requires CYP2C19 bioactivation. AIMS: This study aimed to evaluate the impact of rapid CYP2C19 genotyping at the time of PCI on P2Y12 inhibitor selection and clinical outcomes in real-world patients. METHODS: A total of 974 patients who underwent PCI and rapid CYP2C19 genotyping and received P2Y12 inhibitor treatment were included. P2Y12 inhibitor selection, P2Y12 inhibitor switching, major atherothrombotic events (MAE; a composite of all-cause death, myocardial infarction, ischaemic stroke, stent thrombosis, or unstable angina requiring revascularisation), and bleeding events were assessed throughout the first year post-PCI. Time-varying Cox regression analysis was performed to assess event risk in patients treated with clopidogrel (reference) versus prasugrel/ticagrelor after stratifying by loss-of-function (LOF) status and adjusting for stratum-specific confounders. RESULTS: Clopidogrel was prescribed more frequently at discharge among CYP2C19 non-LOF versus LOF carriers (43% [296/691] vs 31% [87/283]; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL, USA.
- Department of Clinical & Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, GA, USA.
- Division of Cardiology, Department of Medicine, College of Medicine - Jacksonville, University of Florida, Jacksonville, FL, USA.
- Division of Cardiology, Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco", University of Catania, Catania, Italy.
Förderung
- NHGRI NIH HHS
Zitieren
APA
Thomas, C. D., Malave, J. G., Laudani, C., Ortega-Paz, L., Rollini, F., Cavallari, L. H., Angiolillo, D. J., & Franchi, F. (2026). Guided P2Y12 inhibitor selection after rapid CYP2C19 genotyping in patients undergoing percutaneous coronary intervention. EuroIntervention. https://doi.org/10.4244/eij-d-26-00473
Vancouver
Thomas CD, Malave JG, Laudani C, Ortega-Paz L, Rollini F, Cavallari LH, et al. Guided P2Y12 inhibitor selection after rapid CYP2C19 genotyping in patients undergoing percutaneous coronary intervention. EuroIntervention. 2026. doi:10.4244/eij-d-26-00473
BibTeX
@article{Thomas2026,
author = {Thomas, Cameron D and Malave, Jean G and Laudani, Claudio and Ortega-Paz, Luis and Rollini, Fabiana and Cavallari, Larisa H and Angiolillo, Dominick J and Franchi, Francesco},
title = {Guided P2Y12 inhibitor selection after rapid CYP2C19 genotyping in patients undergoing percutaneous coronary intervention},
journal = {EuroIntervention},
year = {2026},
doi = {10.4244/eij-d-26-00473}
}
EUVIMED